1. Overweight and obesity Israel Knesset report 2023
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
3. Kosiborod MN, Bhatta M, Davies M, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2022

For complete information please refer to the updated physician leaflet in the MOH website.

For information on the approved product’s indications, most common adverse events, and significant warnings, enter the following link https://tinyurl.com/ymhuqruo

Need additional information? Contact the Marketing Authorization Holder at: www.novonordisk.co.il